-+ 0.00%
-+ 0.00%
-+ 0.00%

*CorMedix, Heron: Transaction Expected Immediately Accretive to CorMedix Earnings, Free Cash Flow, as Well as Estimated to Generate $45M-$60 M in Near-Term Total Operating Cost Synergies >CRMD

Dow Jones·11/09/2026 12:20:00

Please log in to view news